NCT03526328View on ClinicalTrials.gov

DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma

CompletedOBSERVATIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

August 13, 2019

Study Completion Date

August 13, 2019

Conditions
Barrett's EsophagusEsophageal Adenocarcinoma
Interventions
OTHER

EMR and RFA effect on stem cell marker expression in BE/EAC

Observation of EMR and RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence (Barrett's esophagus/ esophageal adenocarcinoma)

Trial Locations (1)

73104

Gastroenterology, Oklahoma City

All Listed Sponsors
lead

University of Oklahoma

OTHER

NCT03526328 - DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma | Biotech Hunter | Biotech Hunter